Accuray (NASDAQ:ARAY) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Accuray (NASDAQ:ARAY – Free Report) to a hold rating in a research report released on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings cut Accuray from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 1st. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce”.

Check Out Our Latest Report on Accuray

Accuray Stock Performance

Shares of ARAY stock opened at $2.61 on Friday. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.56 and a quick ratio of 0.74. The company’s fifty day simple moving average is $7.54 and its 200-day simple moving average is $13.32. Accuray has a 52 week low of $2.46 and a 52 week high of $45.20.

Accuray (NASDAQ:ARAY – Get Free Report) last announced its quarterly earnings results on Wednesday, August 19th. The medical equipment provider reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.40. Accuray had a negative net margin of 4.41% and a negative return on equity of 35.36%. The firm had revenue of $100.92 million during the quarter, compared to analysts’ expectations of $105.30 million.

Institutional Trading of Accuray

Several large investors have recently bought and sold shares of ARAY. Kovack Advisors Inc. lifted its position in shares of Accuray by 7.1% during the third quarter. Kovack Advisors Inc. now owns 1,125,979 shares of the medical equipment provider’s stock worth $301,000 after purchasing an additional 75,083 shares in the last quarter. Williams & Novak Wealth Management LLC grew its holdings in Accuray by 27.3% during the 3rd quarter. Williams & Novak Wealth Management LLC now owns 303,330 shares of the medical equipment provider’s stock valued at $82,000 after purchasing an additional 65,100 shares in the last quarter. Squarepoint Ops LLC grew its holdings in Accuray by 164.7% during the 2nd quarter. Squarepoint Ops LLC now owns 1,448,234 shares of the medical equipment provider’s stock valued at $373,000 after purchasing an additional 901,158 shares in the last quarter. Susquehanna International Group LLP grew its holdings in Accuray by 2,344.3% during the 2nd quarter. Susquehanna International Group LLP now owns 825,604 shares of the medical equipment provider’s stock valued at $213,000 after purchasing an additional 791,827 shares in the last quarter. Finally, Bank of America Corp DE acquired a new stake in Accuray during the 2nd quarter valued at $28,000. Institutional investors and hedge funds own 64.08% of the company’s stock.

About Accuray

(Get Free Report)

Accuray Incorporated develops, manufactures, and sells radiation therapy systems and related software for treating cancer and other conditions. Its technologies are used by hospitals and cancer treatment centers to plan and deliver radiation treatments. The company’s products include the CyberKnife platform, a robotic system designed to deliver stereotactic radiosurgery and radiation therapy, and the Radixact platform, which uses helical tomotherapy to deliver image-guided radiation treatments. Accuray also provides treatment-planning software, service, and support for its systems.

Further Reading

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.